KRAS and neoplasm: Several recent studies demonstrated that tumor-associated KRAS mutations, that result in abnormal activation of the RAS/Raf1/MEK/ERK pathway, can lead to multiple defects in the type I IFN signaling, thus making KRASMUT cancer cells more permissive to VSV and other OVs (59, –, 63).